This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Pacemakers/ Defibrillators  • Cardiovascular System  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their study on the effects of antiarrhythmic drugs for prevention of shocks from implantable cardioverter defibrillators (ICDs), Dr Connolly and colleagues¹ classified these shocks as appropriate due to ventricular tachycardia or ventricular fibrillation or inappropriate due to supraventricular tachycardia. However, inappropriate shocks could be from other sources that cannot be suppressed by antiarrhythmic medications,² and therefore should not be included in analysis. Such shocks occur as a result of oversensing of T waves in patients with hypertrophic cardiomyopathy, oversensing due to fracture of the leads, or electromagnetic interference from a variety of sources. The authors did not mention the number of such shocks and whether they were excluded from the analysis.

They also did not state whether patients with arrhythmic storm (refractory ventricular tachycardia or ventricular fibrillation) were included in the study. Patients who develop arrhythmic storm are typically sicker, require frequent rehospitalization, have lower left . . . [Full Text of this Article]

Abdul Wase, MD
abdul.wase@wright.edu
Section of Electrophysiology
Good Samaritan Hospital
Wright State University
Dayton, Ohio

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Antiarrhythmic Therapy for Prevention of Implantable Cardioverter Defibrillator Shocks
Michele Coceani
JAMA. 2006;296(10):1229-1230.
EXTRACT | FULL TEXT  

Antiarrhythmic Therapy for Prevention of Implantable Cardioverter Defibrillator Shocks—Reply
Stefan H. Hohnloser, Robin S. Roberts, Eric Fain, and Stuart J. Connolly
JAMA. 2006;296(10):1230.
EXTRACT | FULL TEXT  

Comparison of -Blockers, Amiodarone Plus -Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators: The OPTIC Study: A Randomized Trial
Stuart J. Connolly, Paul Dorian, Robin S. Roberts, Michael Gent, Steven Bailin, Eric S. Fain, Kevin Thorpe, Jean Champagne, Mario Talajic, Benoit Coutu, Gerian C. Gronefeld, Stefan H. Hohnloser, and for the Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators
JAMA. 2006;295(2):165-171.
ABSTRACT | FULL TEXT